Enanta Pharmaceuticals
ENTA
171 hedge funds and large institutions have $1.14B invested in Enanta Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 62 increasing their positions, 63 reducing their positions, and 22 closing their positions.
58% more call options, than puts
Call options by funds: $7.97M | Put options by funds: $5.03M
6% more capital invested
Capital invested by funds: $1.08B → $1.14B (+$62.4M)
2.4% more ownership
Funds ownership: 90.92% → 93.32% (+2.4%)
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
2% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 63
3% less funds holding
Funds holding: 176 → 171 (-5)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$29.5M |
| 2 |
BlackRock
New York
|
+$13.1M |
| 3 |
WG
Winton Group
London,
United Kingdom
|
+$8.33M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7.53M |
| 5 |
Morgan Stanley
New York
|
+$4.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$13.9M |
| 2 |
AC
Armistice Capital
New York
|
-$11.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.85M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$7.8M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$5.71M |
ENTA Hedge Fund Activity: Q4 2019 in Review
171 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2019, worth a combined $1.14B — up 5.8% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ENTA positions and 22 closed out — a net gain of 1 holder — while 62 added to existing stakes and 63 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $29.5M. The largest seller was Janus Henderson Group, cutting an estimated $13.9M.
- 171 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2019, down from 176 in Q3 2019.
- Funds reported $1.14B of Enanta Pharmaceuticals stock for Q4 2019, up 5.8% quarter-over-quarter.
- 23 funds opened new Enanta Pharmaceuticals positions in Q4 2019 and 22 closed out, a net change of +1 holder.
- The largest Enanta Pharmaceuticals buyer in Q4 2019 was Farallon Capital Management, an estimated $29.5M added.
- The largest Enanta Pharmaceuticals seller in Q4 2019 was Janus Henderson Group, an estimated $13.9M sold.
Based on aggregated 13F filings for Q4 2019.